GPX4 and ovarian carcinoma: For example, a study on ovarian cancer using CRISPR-Cas9 screening showed that deletion of the transcription factor PAX8 significantly enhanced the pro-ferroptosis effect of the GPX4 inhibitor RSL3, revealing PAX8 as a novel regulator of GPX4-dependent ferroptosis resistance in tumor cells [104].